Do Cancer Treatments Threaten the Heart?

Cancer treatments can damage the heart, a major issue that influences patient safety and therapeutic choices. This phenomenon, known as cardiac toxicity, manifests in various ways, ranging from a simple elevation of cardiac markers without symptoms to confirmed heart failure. It can occur rapidly or after several years, depending on the type of treatment and the dose administered.

The mechanisms of this toxicity are varied. Some drugs act directly on heart cells, particularly cardiomyocytes, causing structural damage such as cell death, mitochondrial dysfunction, or oxidative stress. These effects are often dose-related and can be irreversible. Other drugs have indirect effects, such as impairing blood vessel function, triggering inflammatory reactions, or disrupting the balance of substances that regulate vessel contraction and dilation. These indirect mechanisms can lead to cardiac arrhythmias, hypertension, or ischemia.

The clinical consequences of this toxicity are multiple. They include left ventricular dysfunction, heart failure, rhythm disorders such as atrial fibrillation or ventricular tachycardia, as well as inflammation of the heart muscle or its lining, coronary artery disease, or even sudden death. Certain medications are particularly associated with these risks. For example, anthracyclines and therapies targeting the HER2 receptor are often linked to heart failure, while others, such as alkylating agents or taxanes, can cause rhythm disorders, ischemia, or pericardial diseases.

Detecting these effects relies on imaging tests such as echocardiography or cardiac MRI, as well as blood markers like troponin or natriuretic peptide. These tools allow for early detection of signs of toxicity, even in the absence of symptoms. Regular monitoring is therefore essential, especially for high-risk patients or those receiving treatments known for their cardiac effects.

Managing this toxicity often involves stopping or reducing the dose of the responsible treatment, as well as introducing protective heart medications, such as beta-blockers or ACE inhibitors. These decisions are made in consultation between oncologists and cardiologists to best balance the effectiveness of cancer treatment and heart protection.

Cardiac toxicity also complicates care management. It can lead to interruption or modification of cancer treatment, which may reduce its effectiveness and increase the risk of disease progression or recurrence. Additionally, it generates extra costs related to cardiac monitoring, specialized consultations, and medications needed to treat side effects.

To limit these risks, preventive strategies are implemented. These include an initial assessment of cardiac risk, regular monitoring during treatment, and, in some cases, the use of liposomal formulations to reduce toxicity. Research is also underway to develop cardioprotective agents capable of preventing or mitigating cardiac damage without compromising the effectiveness of cancer treatments.

Finally, collaboration between oncologists and cardiologists is essential to tailor management to each patient. This multidisciplinary approach allows for personalized monitoring and interventions based on the specific risks related to cancer and its treatment. The goal is to preserve both heart health and the chances of cancer recovery.

Site Sources

Official Study Source

DOI: https://doi.org/10.1007/s11239-026-03336-x

Title: Clinical spectrum and mechanistic insights into cardiotoxicity from cancer therapies

Journal: Journal of Thrombosis and Thrombolysis

Publisher: Springer Science and Business Media LLC

Authors: Richard C. Becker